Humanigen Inc. (HGEN)
| Market Cap | 881.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.27M |
| Shares Out | 43.49M |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | 5.27 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $16.10 |
| Previous Close | $15.21 |
| Change ($) | 0.89 |
| Change (%) | 5.85% |
| Day's Open | 16.09 |
| Day's Range | 15.55 - 16.80 |
| Day's Volume | 920,613 |
| 52-Week Range | 7.75 - 24.64 |
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen awarded two patents, expanding their anti-GM-CSF patent portfolio.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...
Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces the election of Dr. Dale Chappell, the Company's chief scientific officer, to serve as a board director of the Company.
BURLINGAME, Calif. & TUSTIN, Calif.--(BUSINESS WIRE)--Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they hav...
Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ...
SAN DIEGO & BURLINGAME, Calif.--(BUSINESS WIRE)--Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, and ...
Shares of Humanigen Inc. were down 2.5% in trading on Monday after it announced a contract development and manufacturing deal with Emergent BioSolutions Inc. for its experimental COVID-19 trea...
CytoDyn and Humanigen are running high-visibility trials focused on ameliorating COVID-19 acute inflammation. Acute inflammation plays a major role in the hospitalizations and deaths of patien...
GAITHERSBURG, Md. & BURLINGAME, Calif.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered i...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ...
The company announced an important change to one of its ongoing clinical trials.
BURLINGAME, Calif. & CHICAGO--(BUSINESS WIRE)--Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies fo...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytok...
Humanigen (HGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytok...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...
Humanigen starts dosing patients in Phase 3 COVID-19 vaccine trial. AbbVie reports positive topline data for AGN-190584 Phase 3 trial.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...
Shares of Humanigen Inc. HGEN, +24.06% shot up 26% in active morning trading Monday, extending gains after the biopharmaceutical company revealed an upbeat patient case report regarding use of...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response calle...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (Nasdaq: HGEN) (“Humanigen”), announced today that management will present a company overview and business update at the Oppenheimer Fall ...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine sto...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine stor...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.
BURLINGAME, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine sto...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc.
About HGEN
Humanigen, a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Ph... [Read more...]
| Industry Biotechnology | IPO Date Jan 31, 2013 |
| CEO Cameron Durrant | Employees 2 |
| Stock Exchange NASDAQ | Ticker Symbol HGEN |
Analyst Forecasts
According to 6 analysts, the average rating for Humanigen stock is "Buy." The 12-month stock price forecast is 29.33, which is an increase of 82.17% from the latest price.